- Arcutis Canada received Health Canada approval for ZORYVE (roflumilast) cream 0.05% for once-daily topical treatment of mild to moderate atopic dermatitis in children aged 2–5 years, expanding options for preschool-aged patients.
- The approval is supported by the Phase 3 INTEGUMENT-PED study in 652 children, where 25.4% achieved vIGA-AD Success at Week 4 vs 10.7% with vehicle, while 39.4% achieved EASI-75 vs 20.6% with vehicle. Improvements were observed as early as Week 1.
- Long-term data from the INTEGUMENT-OLE extension showed a consistent safety profile through 56 weeks, with treatment-emergent adverse events predominantly mild to moderate.
- The approval expands ZORYVE’s Canadian atopic dermatitis portfolio to younger patients. Roflumilast is a targeted topical PDE4 inhibitor, while the 0.05% cream provides a steroid-free, once-daily option for children 2–5 years with mild to moderate disease.
Takeaways:
Health Canada’s approval of ZORYVE cream 0.05% extends Arcutis’ topical atopic dermatitis franchise into the preschool population, addressing a treatment gap in a disease that frequently begins before age five. The Phase 3 data demonstrate statistically significant improvements in disease clearance and severity versus vehicle, with benefits emerging within the first week. The steroid-free, once-daily formulation, combined with 56-week safety data, could strengthen ZORYVE’s positioning for longer-term management of mild to moderate atopic dermatitis in younger children and broaden Arcutis’ presence in pediatric medical dermatology.
Source: CA Newswire
